APO Research
Talk to an analyst

APO RESEARCH · REPORT

Specific COX-2 Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Specific COX-2 Inhibitors Market Analysis and Forecast 2026-2032

27 December 2025207 pages

Choose your research edition.

Industry ResearchSpecific COX-2 Inhibitors Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Specific COX-2 Inhibitors Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Specific COX-2 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Specific COX-2 Inhibitors Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Specific COX-2 Inhibitors Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Specific COX-2 Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Specific COX-2 Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Specific COX-2 Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Specific COX-2 Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Specific COX-2 Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Specific COX-2 Inhibitors include Actavis, Eskayef Pharmaceuticals, Mylan Pharmaceutical, Neopharmed Gentili, Organon Pharma, Pfizer, Teva, Zentiva and Zydus, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Specific COX-2 Inhibitors, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Specific COX-2 Inhibitors, also provides the sales of main regions and countries. Of the upcoming market potential for Specific COX-2 Inhibitors, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Specific COX-2 Inhibitors sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Specific COX-2 Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Specific COX-2 Inhibitors sales, projected growth trends, production technology, application and end-user industry.

Specific COX-2 Inhibitors Segment by Company

Actavis

Eskayef Pharmaceuticals

Mylan Pharmaceutical

Neopharmed Gentili

Organon Pharma

Pfizer

Teva

Zentiva

Zydus

Beijing Yabao Biological Pharmaceutical

Jiangsu Hengrui Pharmaceuticals

Jiangsu Chiatai Qingjiang Pharmaceutical

Qilu Pharmaceutical

Qingdao Baheal Medical

Shanxi Tongda Pharmaceutical

Sichuan Kelun Pharmaceutical

Specific COX-2 Inhibitors Segment by Type

Etoricoxib

Celecoxib

Imrecoxib

Other

Specific COX-2 Inhibitors Segment by Application

Osteoarthritis and Rheumatoid Arthritis

Relieve Acute Pain

Dysmenorrhea

Other

Specific COX-2 Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Specific COX-2 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Specific COX-2 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Specific COX-2 Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Specific COX-2 Inhibitors in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Specific COX-2 Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Specific COX-2 Inhibitors sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Specific COX-2 Inhibitors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Etoricoxib Major Manufacturers Table 3. Celecoxib Major Manufacturers Table 4. Imrecoxib Major Manufacturers Table 5. Other Major Manufacturers Table 6. Global Specific COX-2 Inhibitors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Osteoarthritis and Rheumatoid Arthritis Major Manufacturers Table 8. Relieve Acute Pain Major Manufacturers Table 9. Dysmenorrhea Major Manufacturers Table 10. Other Major Manufacturers Table 11. Specific COX-2 Inhibitors Industry Trends Table 12. Specific COX-2 Inhibitors Industry Drivers Table 13. Specific COX-2 Inhibitors Industry Opportunities and Challenges Table 14. Specific COX-2 Inhibitors Industry Restraints Table 15. Global Specific COX-2 Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global Specific COX-2 Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 17. Global Specific COX-2 Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 18. Global Specific COX-2 Inhibitors Revenue Market Share by Region (2021-2026) Table 19. Global Specific COX-2 Inhibitors Revenue Market Share by Region (2027-2032) Table 20. Global Specific COX-2 Inhibitors Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 21. Global Specific COX-2 Inhibitors Sales by Region (2021-2026) & (K Units) Table 22. Global Specific COX-2 Inhibitors Sales by Region (2027-2032) & (K Units) Table 23. Global Specific COX-2 Inhibitors Sales Market Share by Region (2021-2026) Table 24. Global Specific COX-2 Inhibitors Sales Market Share by Region (2027-2032) Table 25. Global Specific COX-2 Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Specific COX-2 Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 27. Global Specific COX-2 Inhibitors Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Specific COX-2 Inhibitors Sales Market Share by Manufacturers (2021-2026) Table 29. Global Specific COX-2 Inhibitors Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 30. Global Specific COX-2 Inhibitors Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global Specific COX-2 Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global Specific COX-2 Inhibitors Manufacturers, Product Type & Application Table 33. Global Specific COX-2 Inhibitors Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global Specific COX-2 Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global Specific COX-2 Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Specific COX-2 Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 38. Global Specific COX-2 Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 39. Global Specific COX-2 Inhibitors Revenue Market Share by Type (2021-2026) Table 40. Global Specific COX-2 Inhibitors Revenue Market Share by Type (2027-2032) Table 41. Global Specific COX-2 Inhibitors Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 42. Global Specific COX-2 Inhibitors Sales by Type (2021-2026) & (K Units) Table 43. Global Specific COX-2 Inhibitors Sales by Type (2027-2032) & (K Units) Table 44. Global Specific COX-2 Inhibitors Sales Market Share by Type (2021-2026) Table 45. Global Specific COX-2 Inhibitors Sales Market Share by Type (2027-2032) Table 46. Global Specific COX-2 Inhibitors Price by Type (2021-2026) & (US$/Unit) Table 47. Global Specific COX-2 Inhibitors Price by Type (2027-2032) & (US$/Unit) Table 48. Global Specific COX-2 Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Specific COX-2 Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 50. Global Specific COX-2 Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 51. Global Specific COX-2 Inhibitors Revenue Market Share by Application (2021-2026) Table 52. Global Specific COX-2 Inhibitors Revenue Market Share by Application (2027-2032) Table 53. Global Specific COX-2 Inhibitors Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 54. Global Specific COX-2 Inhibitors Sales by Application (2021-2026) & (K Units) Table 55. Global Specific COX-2 Inhibitors Sales by Application (2027-2032) & (K Units) Table 56. Global Specific COX-2 Inhibitors Sales Market Share by Application (2021-2026) Table 57. Global Specific COX-2 Inhibitors Sales Market Share by Application (2027-2032) Table 58. Global Specific COX-2 Inhibitors Price by Application (2021-2026) & (US$/Unit) Table 59. Global Specific COX-2 Inhibitors Price by Application (2027-2032) & (US$/Unit) Table 60. Actavis Company Information Table 61. Actavis Business Overview Table 62. Actavis Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 63. Actavis Specific COX-2 Inhibitors Product Portfolio Table 64. Actavis Recent Development Table 65. Eskayef Pharmaceuticals Company Information Table 66. Eskayef Pharmaceuticals Business Overview Table 67. Eskayef Pharmaceuticals Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Eskayef Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio Table 69. Eskayef Pharmaceuticals Recent Development Table 70. Mylan Pharmaceutical Company Information Table 71. Mylan Pharmaceutical Business Overview Table 72. Mylan Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Mylan Pharmaceutical Specific COX-2 Inhibitors Product Portfolio Table 74. Mylan Pharmaceutical Recent Development Table 75. Neopharmed Gentili Company Information Table 76. Neopharmed Gentili Business Overview Table 77. Neopharmed Gentili Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Neopharmed Gentili Specific COX-2 Inhibitors Product Portfolio Table 79. Neopharmed Gentili Recent Development Table 80. Organon Pharma Company Information Table 81. Organon Pharma Business Overview Table 82. Organon Pharma Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Organon Pharma Specific COX-2 Inhibitors Product Portfolio Table 84. Organon Pharma Recent Development Table 85. Pfizer Company Information Table 86. Pfizer Business Overview Table 87. Pfizer Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Pfizer Specific COX-2 Inhibitors Product Portfolio Table 89. Pfizer Recent Development Table 90. Teva Company Information Table 91. Teva Business Overview Table 92. Teva Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Teva Specific COX-2 Inhibitors Product Portfolio Table 94. Teva Recent Development Table 95. Zentiva Company Information Table 96. Zentiva Business Overview Table 97. Zentiva Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Zentiva Specific COX-2 Inhibitors Product Portfolio Table 99. Zentiva Recent Development Table 100. Zydus Company Information Table 101. Zydus Business Overview Table 102. Zydus Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Zydus Specific COX-2 Inhibitors Product Portfolio Table 104. Zydus Recent Development Table 105. Beijing Yabao Biological Pharmaceutical Company Information Table 106. Beijing Yabao Biological Pharmaceutical Business Overview Table 107. Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Product Portfolio Table 109. Beijing Yabao Biological Pharmaceutical Recent Development Table 110. Jiangsu Hengrui Pharmaceuticals Company Information Table 111. Jiangsu Hengrui Pharmaceuticals Business Overview Table 112. Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio Table 114. Jiangsu Hengrui Pharmaceuticals Recent Development Table 115. Jiangsu Chiatai Qingjiang Pharmaceutical Company Information Table 116. Jiangsu Chiatai Qingjiang Pharmaceutical Business Overview Table 117. Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Product Portfolio Table 119. Jiangsu Chiatai Qingjiang Pharmaceutical Recent Development Table 120. Qilu Pharmaceutical Company Information Table 121. Qilu Pharmaceutical Business Overview Table 122. Qilu Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Qilu Pharmaceutical Specific COX-2 Inhibitors Product Portfolio Table 124. Qilu Pharmaceutical Recent Development Table 125. Qingdao Baheal Medical Company Information Table 126. Qingdao Baheal Medical Business Overview Table 127. Qingdao Baheal Medical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Qingdao Baheal Medical Specific COX-2 Inhibitors Product Portfolio Table 129. Qingdao Baheal Medical Recent Development Table 130. Shanxi Tongda Pharmaceutical Company Information Table 131. Shanxi Tongda Pharmaceutical Business Overview Table 132. Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Product Portfolio Table 134. Shanxi Tongda Pharmaceutical Recent Development Table 135. Sichuan Kelun Pharmaceutical Company Information Table 136. Sichuan Kelun Pharmaceutical Business Overview Table 137. Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Product Portfolio Table 139. Sichuan Kelun Pharmaceutical Recent Development Table 140. North America Specific COX-2 Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 141. North America Specific COX-2 Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 142. North America Specific COX-2 Inhibitors Sales by Type (2021-2026) & (K Units) Table 143. North America Specific COX-2 Inhibitors Sales by Type (2027-2032) & (K Units) Table 144. North America Specific COX-2 Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 145. North America Specific COX-2 Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 146. North America Specific COX-2 Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 147. North America Specific COX-2 Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 148. North America Specific COX-2 Inhibitors Sales by Application (2021-2026) & (K Units) Table 149. North America Specific COX-2 Inhibitors Sales by Application (2027-2032) & (K Units) Table 150. North America Specific COX-2 Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 151. North America Specific COX-2 Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 152. North America Specific COX-2 Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 153. North America Specific COX-2 Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 154. North America Specific COX-2 Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 155. North America Specific COX-2 Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 156. North America Specific COX-2 Inhibitors Sales by Country (2021-2026) & (K Units) Table 157. North America Specific COX-2 Inhibitors Sales by Country (2027-2032) & (K Units) Table 158. North America Specific COX-2 Inhibitors Sales Price by Country (2021-2026) & (US$/Unit) Table 159. North America Specific COX-2 Inhibitors Sales Price by Country (2027-2032) & (US$/Unit) Table 160. United States Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 161. Canada Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 162. Mexico Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 163. Europe Specific COX-2 Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 164. Europe Specific COX-2 Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 165. Europe Specific COX-2 Inhibitors Sales by Type (2021-2026) & (K Units) Table 166. Europe Specific COX-2 Inhibitors Sales by Type (2027-2032) & (K Units) Table 167. Europe Specific COX-2 Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 168. Europe Specific COX-2 Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 169. Europe Specific COX-2 Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 170. Europe Specific COX-2 Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 171. Europe Specific COX-2 Inhibitors Sales by Application (2021-2026) & (K Units) Table 172. Europe Specific COX-2 Inhibitors Sales by Application (2027-2032) & (K Units) Table 173. Europe Specific COX-2 Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 174. Europe Specific COX-2 Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 175. Europe Specific COX-2 Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 176. Europe Specific COX-2 Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 177. Europe Specific COX-2 Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 178. Europe Specific COX-2 Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 179. Europe Specific COX-2 Inhibitors Sales by Country (2021-2026) & (K Units) Table 180. Europe Specific COX-2 Inhibitors Sales by Country (2027-2032) & (K Units) Table 181. Europe Specific COX-2 Inhibitors Sales Price by Country (2021-2026) & (US$/Unit) Table 182. Europe Specific COX-2 Inhibitors Sales Price by Country (2027-2032) & (US$/Unit) Table 183. Germany Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 184. France Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 185. U.K. Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 186. Italy Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 187. Russia Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 188. Spain Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 189. Netherlands Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 190. Switzerland Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 191. Sweden Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 192. Poland Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 193. China Specific COX-2 Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 194. China Specific COX-2 Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 195. China Specific COX-2 Inhibitors Sales by Type (2021-2026) & (K Units) Table 196. China Specific COX-2 Inhibitors Sales by Type (2027-2032) & (K Units) Table 197. China Specific COX-2 Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 198. China Specific COX-2 Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 199. China Specific COX-2 Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 200. China Specific COX-2 Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 201. China Specific COX-2 Inhibitors Sales by Application (2021-2026) & (K Units) Table 202. China Specific COX-2 Inhibitors Sales by Application (2027-2032) & (K Units) Table 203. China Specific COX-2 Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 204. China Specific COX-2 Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 205. Asia Specific COX-2 Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 206. Asia Specific COX-2 Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 207. Asia Specific COX-2 Inhibitors Sales by Type (2021-2026) & (K Units) Table 208. Asia Specific COX-2 Inhibitors Sales by Type (2027-2032) & (K Units) Table 209. Asia Specific COX-2 Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 210. Asia Specific COX-2 Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 211. Asia Specific COX-2 Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 212. Asia Specific COX-2 Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 213. Asia Specific COX-2 Inhibitors Sales by Application (2021-2026) & (K Units) Table 214. Asia Specific COX-2 Inhibitors Sales by Application (2027-2032) & (K Units) Table 215. Asia Specific COX-2 Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 216. Asia Specific COX-2 Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 217. Asia Specific COX-2 Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 218. Asia Specific COX-2 Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 219. Asia Specific COX-2 Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 220. Asia Specific COX-2 Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 221. Asia Specific COX-2 Inhibitors Sales by Country (2021-2026) & (K Units) Table 222. Asia Specific COX-2 Inhibitors Sales by Country (2027-2032) & (K Units) Table 223. Asia Specific COX-2 Inhibitors Sales Price by Country (2021-2026) & (US$/Unit) Table 224. Asia Specific COX-2 Inhibitors Sales Price by Country (2027-2032) & (US$/Unit) Table 225. Japan Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 226. South Korea Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 227. India Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 228. Australia Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 229. Taiwan Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 230. Southeast Asia Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 231. SAMEA Specific COX-2 Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 232. SAMEA Specific COX-2 Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 233. SAMEA Specific COX-2 Inhibitors Sales by Type (2021-2026) & (K Units) Table 234. SAMEA Specific COX-2 Inhibitors Sales by Type (2027-2032) & (K Units) Table 235. SAMEA Specific COX-2 Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 236. SAMEA Specific COX-2 Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 237. SAMEA Specific COX-2 Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 238. SAMEA Specific COX-2 Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 239. SAMEA Specific COX-2 Inhibitors Sales by Application (2021-2026) & (K Units) Table 240. SAMEA Specific COX-2 Inhibitors Sales by Application (2027-2032) & (K Units) Table 241. SAMEA Specific COX-2 Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 242. SAMEA Specific COX-2 Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 243. SAMEA Specific COX-2 Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 244. SAMEA Specific COX-2 Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 245. SAMEA Specific COX-2 Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 246. SAMEA Specific COX-2 Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 247. SAMEA Specific COX-2 Inhibitors Sales by Country (2021-2026) & (K Units) Table 248. SAMEA Specific COX-2 Inhibitors Sales by Country (2027-2032) & (K Units) Table 249. SAMEA Specific COX-2 Inhibitors Sales Price by Country (2021-2026) & (US$/Unit) Table 250. SAMEA Specific COX-2 Inhibitors Sales Price by Country (2027-2032) & (US$/Unit) Table 251. Brazil Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 252. Argentina Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 253. Chile Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 254. Colombia Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 255. Peru Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 256. Saudi Arabia Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 257. Israel Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 258. UAE Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 259. Turkey Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 260. Iran Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 261. Egypt Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Table 262. Key Raw Materials Table 263. Raw Materials Key Suppliers Table 264. Specific COX-2 Inhibitors Distributors List Table 265. Specific COX-2 Inhibitors Customers List Table 266. Research Programs/Design for This Report Table 267. Authors List of This Report Table 268. Secondary Sources Table 269. Primary Sources List of Figures Figure 1. Specific COX-2 Inhibitors Image Figure 2. Global Specific COX-2 Inhibitors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Specific COX-2 Inhibitors Market Size Share 2021 VS 2025 VS 2032 Figure 4. Etoricoxib Image Figure 5. Celecoxib Image Figure 6. Imrecoxib Image Figure 7. Other Image Figure 8. Global Specific COX-2 Inhibitors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Specific COX-2 Inhibitors Market Size Share 2021 VS 2025 VS 2032 Figure 10. Osteoarthritis and Rheumatoid Arthritis Image Figure 11. Relieve Acute Pain Image Figure 12. Dysmenorrhea Image Figure 13. Other Image Figure 14. Global Specific COX-2 Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Specific COX-2 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 16. Global Specific COX-2 Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global Specific COX-2 Inhibitors Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global Specific COX-2 Inhibitors Revenue Market Share by Region (2021-2032) Figure 19. Global Specific COX-2 Inhibitors Sales (2021-2032) & (K Units) Figure 20. Global Specific COX-2 Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 21. Global Specific COX-2 Inhibitors Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico Specific COX-2 Inhibitors Sales YoY (2021-2032) & (K Units) Figure 23. Europe Specific COX-2 Inhibitors Sales YoY (2021-2032) & (K Units) Figure 24. China Specific COX-2 Inhibitors Sales YoY (2021-2032) & (K Units) Figure 25. Asia (Excluding China) Specific COX-2 Inhibitors Sales YoY (2021-2032) & (K Units) Figure 26. South America, Middle East and Africa Specific COX-2 Inhibitors Sales YoY (2021-2032) & (K Units) Figure 27. Global Specific COX-2 Inhibitors Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global Specific COX-2 Inhibitors Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global Specific COX-2 Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Specific COX-2 Inhibitors Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Specific COX-2 Inhibitors Revenue Market Share by Type (2021-2032) Figure 33. Global Specific COX-2 Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 34. Global Specific COX-2 Inhibitors Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global Specific COX-2 Inhibitors Sales Market Share by Type (2021-2032) Figure 36. Global Specific COX-2 Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 37. Global Specific COX-2 Inhibitors Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Specific COX-2 Inhibitors Revenue Market Share by Application (2021-2032) Figure 39. Global Specific COX-2 Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 40. Global Specific COX-2 Inhibitors Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global Specific COX-2 Inhibitors Sales Market Share by Application (2021-2032) Figure 42. North America Specific COX-2 Inhibitors Revenue Share by Type (2021-2032) Figure 43. North America Specific COX-2 Inhibitors Sales Share by Type (2021-2032) Figure 44. North America Specific COX-2 Inhibitors Revenue Share by Application (2021-2032) Figure 45. North America Specific COX-2 Inhibitors Sales Share by Application (2021-2032) Figure 46. North America Specific COX-2 Inhibitors Revenue Share by Country (2021-2032) Figure 47. North America Specific COX-2 Inhibitors Sales Share by Country (2021-2032) Figure 48. Europe Specific COX-2 Inhibitors Revenue Share by Type (2021-2032) Figure 49. Europe Specific COX-2 Inhibitors Sales Share by Type (2021-2032) Figure 50. Europe Specific COX-2 Inhibitors Revenue Share by Application (2021-2032) Figure 51. Europe Specific COX-2 Inhibitors Sales Share by Application (2021-2032) Figure 52. Europe Specific COX-2 Inhibitors Revenue Share by Country (2021-2032) Figure 53. Europe Specific COX-2 Inhibitors Sales Share by Country (2021-2032) Figure 54. China Specific COX-2 Inhibitors Revenue Share by Type (2021-2032) Figure 55. China Specific COX-2 Inhibitors Sales Share by Type (2021-2032) Figure 56. China Specific COX-2 Inhibitors Revenue Share by Application (2021-2032) Figure 57. China Specific COX-2 Inhibitors Sales Share by Application (2021-2032) Figure 58. Asia Specific COX-2 Inhibitors Revenue Share by Type (2021-2032) Figure 59. Asia Specific COX-2 Inhibitors Sales Share by Type (2021-2032) Figure 60. Asia Specific COX-2 Inhibitors Revenue Share by Application (2021-2032) Figure 61. Asia Specific COX-2 Inhibitors Sales Share by Application (2021-2032) Figure 62. Asia Specific COX-2 Inhibitors Revenue Share by Country (2021-2032) Figure 63. Asia Specific COX-2 Inhibitors Sales Share by Country (2021-2032) Figure 64. SAMEA Specific COX-2 Inhibitors Revenue Share by Type (2021-2032) Figure 65. SAMEA Specific COX-2 Inhibitors Sales Share by Type (2021-2032) Figure 66. SAMEA Specific COX-2 Inhibitors Revenue Share by Application (2021-2032) Figure 67. SAMEA Specific COX-2 Inhibitors Sales Share by Application (2021-2032) Figure 68. SAMEA Specific COX-2 Inhibitors Revenue Share by Country (2021-2032) Figure 69. SAMEA Specific COX-2 Inhibitors Sales Share by Country (2021-2032) Figure 70. Specific COX-2 Inhibitors Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Specific COX-2 Inhibitors Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Etoricoxib
  • Celecoxib
  • Imrecoxib
  • Other
Applications
  • Osteoarthritis and Rheumatoid Arthritis
  • Relieve Acute Pain
  • Dysmenorrhea
  • Other
Companies covered
  • Actavis
  • Eskayef Pharmaceuticals
  • Mylan Pharmaceutical
  • Neopharmed Gentili
  • Organon Pharma
  • Pfizer
  • Teva
  • Zentiva
  • Zydus
  • Beijing Yabao Biological Pharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Jiangsu Chiatai Qingjiang Pharmaceutical
  • Qilu Pharmaceutical
  • Qingdao Baheal Medical
  • Shanxi Tongda Pharmaceutical
  • Sichuan Kelun Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Specific COX-2 Inhibitors Market by Type
  3. 1.2.1 Global Specific COX-2 Inhibitors Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Etoricoxib
  5. 1.2.3 Celecoxib
  6. 1.2.4 Imrecoxib
  7. 1.2.5 Other
  8. 1.3 Specific COX-2 Inhibitors Market by Application
  9. 1.3.1 Global Specific COX-2 Inhibitors Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Osteoarthritis and Rheumatoid Arthritis
  11. 1.3.3 Relieve Acute Pain
  12. 1.3.4 Dysmenorrhea
  13. 1.3.5 Other
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Specific COX-2 Inhibitors Market Dynamics
  1. 2.1 Specific COX-2 Inhibitors Industry Trends
  2. 2.2 Specific COX-2 Inhibitors Industry Drivers
  3. 2.3 Specific COX-2 Inhibitors Industry Opportunities and Challenges
  4. 2.4 Specific COX-2 Inhibitors Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Specific COX-2 Inhibitors Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Specific COX-2 Inhibitors Revenue by Region
  3. 3.2.1 Global Specific COX-2 Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Specific COX-2 Inhibitors Revenue by Region (2021-2026)
  5. 3.2.3 Global Specific COX-2 Inhibitors Revenue by Region (2027-2032)
  6. 3.2.4 Global Specific COX-2 Inhibitors Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Specific COX-2 Inhibitors Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Specific COX-2 Inhibitors Sales by Region
  9. 3.4.1 Global Specific COX-2 Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Specific COX-2 Inhibitors Sales by Region (2021-2026)
  11. 3.4.3 Global Specific COX-2 Inhibitors Sales by Region (2027-2032)
  12. 3.4.4 Global Specific COX-2 Inhibitors Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Specific COX-2 Inhibitors Revenue by Manufacturers
  2. 4.1.1 Global Specific COX-2 Inhibitors Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Specific COX-2 Inhibitors Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Specific COX-2 Inhibitors Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Specific COX-2 Inhibitors Sales by Manufacturers
  6. 4.2.1 Global Specific COX-2 Inhibitors Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Specific COX-2 Inhibitors Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Specific COX-2 Inhibitors Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Specific COX-2 Inhibitors Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Specific COX-2 Inhibitors Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Specific COX-2 Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Specific COX-2 Inhibitors Manufacturers, Product Type & Application
  13. 4.7 Global Specific COX-2 Inhibitors Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Specific COX-2 Inhibitors Market CR5 and HHI
  16. 4.8.2 2025 Specific COX-2 Inhibitors Tier 1, Tier 2, and Tier 3
5 Specific COX-2 Inhibitors Market by Type
  1. 5.1 Global Specific COX-2 Inhibitors Revenue by Type
  2. 5.1.1 Global Specific COX-2 Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Specific COX-2 Inhibitors Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Specific COX-2 Inhibitors Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Specific COX-2 Inhibitors Sales by Type
  6. 5.2.1 Global Specific COX-2 Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Specific COX-2 Inhibitors Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Specific COX-2 Inhibitors Sales Market Share by Type (2021-2032)
  9. 5.3 Global Specific COX-2 Inhibitors Price by Type
6 Specific COX-2 Inhibitors Market by Application
  1. 6.1 Global Specific COX-2 Inhibitors Revenue by Application
  2. 6.1.1 Global Specific COX-2 Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Specific COX-2 Inhibitors Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Specific COX-2 Inhibitors Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Specific COX-2 Inhibitors Sales by Application
  6. 6.2.1 Global Specific COX-2 Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Specific COX-2 Inhibitors Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Specific COX-2 Inhibitors Sales Market Share by Application (2021-2032)
  9. 6.3 Global Specific COX-2 Inhibitors Price by Application
7 Company Profiles
  1. 7.1 Actavis
  2. 7.1.1 Actavis Company Information
  3. 7.1.2 Actavis Business Overview
  4. 7.1.3 Actavis Specific COX-2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Actavis Specific COX-2 Inhibitors Product Portfolio
  6. 7.1.5 Actavis Recent Developments
  7. 7.2 Eskayef Pharmaceuticals
  8. 7.2.1 Eskayef Pharmaceuticals Company Information
  9. 7.2.2 Eskayef Pharmaceuticals Business Overview
  10. 7.2.3 Eskayef Pharmaceuticals Specific COX-2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Eskayef Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio
  12. 7.2.5 Eskayef Pharmaceuticals Recent Developments
  13. 7.3 Mylan Pharmaceutical
  14. 7.3.1 Mylan Pharmaceutical Company Information
  15. 7.3.2 Mylan Pharmaceutical Business Overview
  16. 7.3.3 Mylan Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Mylan Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
  18. 7.3.5 Mylan Pharmaceutical Recent Developments
  19. 7.4 Neopharmed Gentili
  20. 7.4.1 Neopharmed Gentili Company Information
  21. 7.4.2 Neopharmed Gentili Business Overview
  22. 7.4.3 Neopharmed Gentili Specific COX-2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Neopharmed Gentili Specific COX-2 Inhibitors Product Portfolio
  24. 7.4.5 Neopharmed Gentili Recent Developments
  25. 7.5 Organon Pharma
  26. 7.5.1 Organon Pharma Company Information
  27. 7.5.2 Organon Pharma Business Overview
  28. 7.5.3 Organon Pharma Specific COX-2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Organon Pharma Specific COX-2 Inhibitors Product Portfolio
  30. 7.5.5 Organon Pharma Recent Developments
  31. 7.6 Pfizer
  32. 7.6.1 Pfizer Company Information
  33. 7.6.2 Pfizer Business Overview
  34. 7.6.3 Pfizer Specific COX-2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Pfizer Specific COX-2 Inhibitors Product Portfolio
  36. 7.6.5 Pfizer Recent Developments
  37. 7.7 Teva
  38. 7.7.1 Teva Company Information
  39. 7.7.2 Teva Business Overview
  40. 7.7.3 Teva Specific COX-2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Teva Specific COX-2 Inhibitors Product Portfolio
  42. 7.7.5 Teva Recent Developments
  43. 7.8 Zentiva
  44. 7.8.1 Zentiva Company Information
  45. 7.8.2 Zentiva Business Overview
  46. 7.8.3 Zentiva Specific COX-2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Zentiva Specific COX-2 Inhibitors Product Portfolio
  48. 7.8.5 Zentiva Recent Developments
  49. 7.9 Zydus
  50. 7.9.1 Zydus Company Information
  51. 7.9.2 Zydus Business Overview
  52. 7.9.3 Zydus Specific COX-2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Zydus Specific COX-2 Inhibitors Product Portfolio
  54. 7.9.5 Zydus Recent Developments
  55. 7.10 Beijing Yabao Biological Pharmaceutical
  56. 7.10.1 Beijing Yabao Biological Pharmaceutical Company Information
  57. 7.10.2 Beijing Yabao Biological Pharmaceutical Business Overview
  58. 7.10.3 Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
  60. 7.10.5 Beijing Yabao Biological Pharmaceutical Recent Developments
  61. 7.11 Jiangsu Hengrui Pharmaceuticals
  62. 7.11.1 Jiangsu Hengrui Pharmaceuticals Company Information
  63. 7.11.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  64. 7.11.3 Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio
  66. 7.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  67. 7.12 Jiangsu Chiatai Qingjiang Pharmaceutical
  68. 7.12.1 Jiangsu Chiatai Qingjiang Pharmaceutical Company Information
  69. 7.12.2 Jiangsu Chiatai Qingjiang Pharmaceutical Business Overview
  70. 7.12.3 Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
  72. 7.12.5 Jiangsu Chiatai Qingjiang Pharmaceutical Recent Developments
  73. 7.13 Qilu Pharmaceutical
  74. 7.13.1 Qilu Pharmaceutical Company Information
  75. 7.13.2 Qilu Pharmaceutical Business Overview
  76. 7.13.3 Qilu Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Qilu Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
  78. 7.13.5 Qilu Pharmaceutical Recent Developments
  79. 7.14 Qingdao Baheal Medical
  80. 7.14.1 Qingdao Baheal Medical Company Information
  81. 7.14.2 Qingdao Baheal Medical Business Overview
  82. 7.14.3 Qingdao Baheal Medical Specific COX-2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Qingdao Baheal Medical Specific COX-2 Inhibitors Product Portfolio
  84. 7.14.5 Qingdao Baheal Medical Recent Developments
  85. 7.15 Shanxi Tongda Pharmaceutical
  86. 7.15.1 Shanxi Tongda Pharmaceutical Company Information
  87. 7.15.2 Shanxi Tongda Pharmaceutical Business Overview
  88. 7.15.3 Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
  90. 7.15.5 Shanxi Tongda Pharmaceutical Recent Developments
  91. 7.16 Sichuan Kelun Pharmaceutical
  92. 7.16.1 Sichuan Kelun Pharmaceutical Company Information
  93. 7.16.2 Sichuan Kelun Pharmaceutical Business Overview
  94. 7.16.3 Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
  96. 7.16.5 Sichuan Kelun Pharmaceutical Recent Developments
8 North America
  1. 8.1 North America Specific COX-2 Inhibitors Market Size by Type
  2. 8.1.1 North America Specific COX-2 Inhibitors Revenue by Type (2021-2032)
  3. 8.1.2 North America Specific COX-2 Inhibitors Sales by Type (2021-2032)
  4. 8.1.3 North America Specific COX-2 Inhibitors Price by Type (2021-2032)
  5. 8.2 North America Specific COX-2 Inhibitors Market Size by Application
  6. 8.2.1 North America Specific COX-2 Inhibitors Revenue by Application (2021-2032)
  7. 8.2.2 North America Specific COX-2 Inhibitors Sales by Application (2021-2032)
  8. 8.2.3 North America Specific COX-2 Inhibitors Price by Application (2021-2032)
  9. 8.3 North America Specific COX-2 Inhibitors Market Size by Country
  10. 8.3.1 North America Specific COX-2 Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Specific COX-2 Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Specific COX-2 Inhibitors Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Specific COX-2 Inhibitors Market Size by Type
  2. 9.1.1 Europe Specific COX-2 Inhibitors Revenue by Type (2021-2032)
  3. 9.1.2 Europe Specific COX-2 Inhibitors Sales by Type (2021-2032)
  4. 9.1.3 Europe Specific COX-2 Inhibitors Price by Type (2021-2032)
  5. 9.2 Europe Specific COX-2 Inhibitors Market Size by Application
  6. 9.2.1 Europe Specific COX-2 Inhibitors Revenue by Application (2021-2032)
  7. 9.2.2 Europe Specific COX-2 Inhibitors Sales by Application (2021-2032)
  8. 9.2.3 Europe Specific COX-2 Inhibitors Price by Application (2021-2032)
  9. 9.3 Europe Specific COX-2 Inhibitors Market Size by Country
  10. 9.3.1 Europe Specific COX-2 Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Specific COX-2 Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Specific COX-2 Inhibitors Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Specific COX-2 Inhibitors Market Size by Type
  2. 10.1.1 China Specific COX-2 Inhibitors Revenue by Type (2021-2032)
  3. 10.1.2 China Specific COX-2 Inhibitors Sales by Type (2021-2032)
  4. 10.1.3 China Specific COX-2 Inhibitors Price by Type (2021-2032)
  5. 10.2 China Specific COX-2 Inhibitors Market Size by Application
  6. 10.2.1 China Specific COX-2 Inhibitors Revenue by Application (2021-2032)
  7. 10.2.2 China Specific COX-2 Inhibitors Sales by Application (2021-2032)
  8. 10.2.3 China Specific COX-2 Inhibitors Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Specific COX-2 Inhibitors Market Size by Type
  2. 11.1.1 Asia Specific COX-2 Inhibitors Revenue by Type (2021-2032)
  3. 11.1.2 Asia Specific COX-2 Inhibitors Sales by Type (2021-2032)
  4. 11.1.3 Asia Specific COX-2 Inhibitors Price by Type (2021-2032)
  5. 11.2 Asia Specific COX-2 Inhibitors Market Size by Application
  6. 11.2.1 Asia Specific COX-2 Inhibitors Revenue by Application (2021-2032)
  7. 11.2.2 Asia Specific COX-2 Inhibitors Sales by Application (2021-2032)
  8. 11.2.3 Asia Specific COX-2 Inhibitors Price by Application (2021-2032)
  9. 11.3 Asia Specific COX-2 Inhibitors Market Size by Country
  10. 11.3.1 Asia Specific COX-2 Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Specific COX-2 Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Specific COX-2 Inhibitors Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Specific COX-2 Inhibitors Market Size by Type
  2. 12.1.1 SAMEA Specific COX-2 Inhibitors Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Specific COX-2 Inhibitors Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Specific COX-2 Inhibitors Price by Type (2021-2032)
  5. 12.2 SAMEA Specific COX-2 Inhibitors Market Size by Application
  6. 12.2.1 SAMEA Specific COX-2 Inhibitors Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Specific COX-2 Inhibitors Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Specific COX-2 Inhibitors Price by Application (2021-2032)
  9. 12.3 SAMEA Specific COX-2 Inhibitors Market Size by Country
  10. 12.3.1 SAMEA Specific COX-2 Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Specific COX-2 Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Specific COX-2 Inhibitors Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Specific COX-2 Inhibitors Value Chain Analysis
  2. 13.1.1 Specific COX-2 Inhibitors Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Specific COX-2 Inhibitors Production Mode & Process
  6. 13.2 Specific COX-2 Inhibitors Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Specific COX-2 Inhibitors Distributors
  9. 13.2.3 Specific COX-2 Inhibitors Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst